For US risk-bearing primary care
Turn fragmented longitudinal records into prioritized physician review.
PULSE reconstructs the available longitudinal record, identifies clinically relevant change, forecasts where it may be heading, and presents traceable next-action and medication candidates for physician review.
01
Connected record
Labs · diagnoses · medications · encounters · notes
- LabseGFR, UACR, HbA1c, KMay 12, 2024
- DiagnosesType 2 diabetes, hypertensionApr 28, 2024
- MedicationsACE inhibitor, metforminMay 10, 2024
- Encounters + notesPCP visit, nephrology, assessment planMay 8, 2024
02
Observed + forecast
eGFR (mL/min/1.73m²)
03
Physician review
- Next-action candidate
- Repeat renal panel
- Assess trend and risk
- Medication candidate
- Review SGLT2 inhibitor eligibility
- Consider per guideline
Trace to source
Programs and institutional support
Primary commercial focus
Built first for US risk-bearing primary care
PULSE is designed for US organizations accountable for outcomes across defined patient populations, including ACOs, MSOs, Medicare Advantage-oriented provider groups, and multisite care networks. It can also support other US healthcare organizations working with longitudinal clinical data.
Risk-bearing primary care in detail- 01Reconstruct the trajectory
- Organize available laboratory results, diagnoses, medications, encounters, and notes in clinical order.
- 02Review change with context
- See longitudinal direction, missing-data intervals, and forecast uncertainty against the patient's own recorded history.
- 03Keep findings traceable
- Connect each finding to supporting observations, relevant medical evidence, and the physician's review decision.
Interactive illustrative case
From longitudinal record to one traceable review finding
Explore the synthetic case across its timeline, forecast, clinical signals, evidence sources, and physician-review step.
PULSE · patient trajectory
Interactive · Case 04-118
Select a view, then trace the prioritised finding to its source or physician-review step.
HbA1c %
observed 2018–2026 · projected to 2028
- 2019DiagnosisType 2 diabetes
- 2024DiagnosisMicroalbuminuria
- 2025MedicationRamipril increased
- 2022–23Gap11 months without laboratory data
HbA1c %
observed 2018–2026 · projected to 2028
- 2019DiagnosisType 2 diabetes
- 2024DiagnosisMicroalbuminuria
- 2025MedicationRamipril increased
- 2022–23Gap11 months without laboratory data
Illustrative patient data
What is available today
Retrospective evaluation is in progress.
- Available for demonstration
- Longitudinal record reconstruction, trajectory view, evidence and provenance, and the physician-review interface.
- Under evaluation
- Forecasting performance, physician agreement, omissions, calibration, and workflow fit.
- Engagement-specific
- Integrations, deployment, security terms, and permitted data scope.
Scientific foundation
Research behind patient trajectory intelligence
Dr.MaxHealth researches longitudinal patient modeling, biomarker forecasting, trained medical orchestration, evidence-grounded reasoning, and physician-led evaluation.
Founded by researchers with peer-reviewed work in Nature Microbiology, Cell Reports, PNAS, Viruses, and Talanta.
Explore the ScienceEvaluate PULSE on an illustrative case and your clinical workflow
Review the current product, discuss your data environment, and outline a bounded retrospective evaluation for your organization.
PULSE is designed to support qualified healthcare professionals and does not replace clinical judgment.